Jeanette Dilley
About
In The Last Decade
Jeanette Dilley
31 papers receiving 2.3k citations
Peers
Comparison fields: 5 of 91
- Molecular Biology 978
- Immunology 930
- Radiology, Nuclear Medicine and Imaging 776
- Genetics 699
- Oncology 599
Countries citing papers authored by Jeanette Dilley
This map shows the geographic impact of Jeanette Dilley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeanette Dilley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeanette Dilley more than expected).
Fields of papers citing papers by Jeanette Dilley
This network shows the impact of papers produced by Jeanette Dilley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeanette Dilley. The network helps show where Jeanette Dilley may publish in the future.
Co-authorship network of co-authors of Jeanette Dilley
This figure shows the co-authorship network connecting the top 25 collaborators of Jeanette Dilley. A scholar is included among the top collaborators of Jeanette Dilley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeanette Dilley. Jeanette Dilley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 110 | |
| 3 | 90 | |
| 4 | 175 | |
| 5 | 89 | |
| 6 | 43 | |
| 7 | 69 | |
| 8 | Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. | 45 |
| 9 | Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. | 57 |
| 10 | Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. | 146 |
| 11 | CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. | 129 |
| 12 | The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. | 186 |
| 13 | 5 | |
| 14 | 53 | |
| 15 | 307 | |
| 16 | 137 | |
| 17 | 24 | |
| 18 | 9 | |
| 19 | 60 | |
| 20 | 46 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.